SEARCH

SEARCH BY CITATION

References

  • 1
    Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004; 89: 25839.
  • 2
    Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 254856.
  • 3
    Frezza EE, Wachtel MS, Chiriva-Internati M. Influence of obesity on the risk of developing colon cancer. Gut 2006; 55: 28591.
  • 4
    Märin P, Andersson B, Ottosson M, et al. The morphology and metabolism of intraabdominal adipose tissue in men. Metabolism 1992; 41: 12428.
  • 5
    Larsson B, Svärdsudd K, Welin L, Wilhemlsen L, Björntörp P, Tibblin G. Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death: 13 year follow-up of participants in the study of men born in 1913. Br Med J (Clin Res Ed) 1984; 288: 14014.
  • 6
    Ross R, Leger L, Morris D, De Guise J, Guardo R. Quantification of adipose tissue by MRI: relationship with anthropometric variables. J Appl Physiol 1992; 72: 78795.
  • 7
    Chowdhury B, Sjöström L, Alpsten M, Kostanty J, Kvist H, Löfgren R. A multicompartment body composition technique based on computerized tomography. Int J Obes Relat Metab Disord 1994; 18: 21934.
  • 8
    Ashwell M, Cole TJ, Dixon AK. Obesity: new insight into the anthropometric classification of fat distribution shown by computed tomography. Br Med J (Clin Res Ed) 1985; 290: 16924.
  • 9
    Ferland M, Desprès J-P, Tremblay A, et al. Assessment of adipose tissue distribution by computed axial tomography in obese women: association with body density and anthropometric measurements. Br J Nutr 1989; 61: 13948.
  • 10
    Frayn KN, Karpe F, Fielding BA, Macdonald IA, Coppack SW. Integrative physiology of human adipose tissue. Int J Obes Relat Metab Disord 2003; 27: 87588.
  • 11
    Gregoire FM, Smas CM, Sul HS. Understanding adipocyte differentiation. Phys Rev 1998; 78: 783809.
  • 12
    Entenmann G, Hauner H. Relationship between replication and differentiation in cultured human adipocyte precursor cells. Am J Physiol (Cell Physiol) 1996; 270 (4 pt 1): C10116.
  • 13
    Feve B, Emorine LJ, Briend-Sutren MM, Lasnier F, Strosberg AD, Pairault J. Differential regulation of beta1- and beta2-adrenergic receptor protein and mRNA levels by glucocorticcoids during 3T3-F442A adipose differentiation. J Biol Chem 1990; 265: 163439.
  • 14
    Feve B, Emorine LJ, Briend-Sutren MM, Lasnier F, Strosberg AD, Pairault J. A typical beta-adrenergic receptor in 3T3-F442A adipocytes. Pharmacological and molecular relationship with the human beta 3-adrenergic receptor. J Biol Chem 1991; 266: 2032936.
  • 15
    Cousin B, Munoz O, Andre M, et al. A role for preadipocytes as macrophage like cells. FASEB J 1999; 13: 30512.
  • 16
    Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 182130.
  • 17
    Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1808.
  • 18
    Charriere G, Cousin B, Arnaud E, et al. Preadipocyte conversion to macrophage. Evidence of plasticity. J Biol Chem 2003; 278: 98505.
  • 19
    Sierra-Honigmann MR, Nath AK, Murakami C, et al. Biological action of leptin as an angiogenic factor. Science 1998; 281: 16836.
  • 20
    Ron D, Brasier AR, McGehee RE Jr, Habener JF. Tumor necrosis factor-induced reversal of adipocytic phenotype of 3T3-L1 cells is preceded by a loss of nuclear CCAAT/enhancer binding protein (C/EBP). J Clin Invest 1992; 89: 2223233.
  • 21
    Zhang B, Berger J, Hu E, et al. Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha. Mol Endocrinol 1996; 10: 145766.
  • 22
    Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92: 34755.
  • 23
    Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 8791.
  • 24
    Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003; 24: 278301.
  • 25
    Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A 2003; 100: 726570.
  • 26
    Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev 2002; 3: 85101.
  • 27
    Cianflone K, Xia Z, Chen LY. Critical review of acylation-stimulating protein physiology in humans and rodents. Biochem Biophys Acta 2003; 1609: 12743.
  • 28
    Silha JV, Krsek M, Sucharda P, Murphy LJ. Angiogenic factors are elevated in overweight and obese individuals. Int J Obes 2005; 29: 130814.
  • 29
    Hausman DB, DiGirolamo M, Bartness TJ, Hausman GJ, Martin RJ. The biology of white adipocyte proliferation. Obes Rev 2001; 2: 23954.
  • 30
    Gerhardt CC, Romero IA, Cancello R, Camoin L, Strosberg AD. Chemokines control fat accumulation and leptin secretion by cultured human adipocytes. Mol Cell Endocrinol 2000; 175: 8192.
  • 31
    Somm E, Cettour-Rose P, Asensio C, et al. Interleukin-1 receptor antagonist is upregulated during diet-induced obesity and regulates insulin sensitivity in rodents. Diabetologia 2006; 49: 38793.
  • 32
    Fain JN, Tichansky DS, Madan AK. Transforming growth factor beta1 release by human adipose tissue is enhanced in obesity. Metabolism 2005; 54: 154651.
  • 33
    Okuno A, Tamemoto H, Tobe K, et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998; 101: 135461.
  • 34
    Yamouchi T, Kamon J, Waki H, et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 2001; 276: 4124554.
  • 35
    Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003; 26: 244250.
  • 36
    Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003; 148: 293300.
  • 37
    Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev 1994; 74: 761811.
  • 38
    Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004; 306: 45761.
  • 39
    Browlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 81320.
  • 40
    Hopfl G, Ogunshola O, Gassmann M. HIFs and tumors – causes and consequences. Am J Physiol Regul Integr Comp Physiol 2004; 286: R60823.
  • 41
    Wenger RH. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J 2002; 16: 115162.
  • 42
    Zick Y. Role of Ser/Thr kinases in the uncoupling of insulin signaling. Int J Obes Relat Metab Disord 2003; 27 (Suppl. 3): S5660.
  • 43
    Shoelson SE, Lee J, Yuan M. Inflammation and the IKK beta/I kappa B/NFkappa B axis in obesity- and diet-induced resistance. Int J Obes Relat Metab Disord 2003; 27(Suppl. 3): S4952.
  • 44
    Van Dielen FM, Buurman WA, Hadfoune M, Nijhuis J, Greve JW. Macrophage inhibitory factor, plasminogen activator inhibitor-1, other acute phase proteins, and inflammatory mediators normalize as a result of weight loss in morbidly obese subjects treated with gastric restrictive surgery. J Clin Endocrinol Metab 2004; 89: 40628.
  • 45
    Yesilbursa D, Serdar A, Heper Y, et al. The effect of orlistat-induced weight loss on interleukin-6 and C-reactive protein levels in obese subjects. Acta Cardiol 2005; 60: 2659.
  • 46
    Ryan AS, Nicklas BJ. Reductions in plasma cytokine levels with weight loss improve insulin sensitivity in overweight and obese postmenopausal women. Diabetes Care 2004; 27: 1699705.
  • 47
    Mendall MA, Patel P, Asante M, et al. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart 1997; 78: 2737.
  • 48
    Tataranni PA, Ortega E A burning question: does an adipokine-induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes? Diabetes 2005; 54: 91727.
  • 49
    Nieman DC, Henson DA, Nehlsen-Cannarella SL, et al. Influence of obesity on immune function. J Am Diet Assoc 1999; 99: 2949.
  • 50
    Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 2004; 110: 156471.
  • 51
    Bjorkbacka H, Kunjathoor VV, Moore KJ, et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004; 10: 41621.
  • 52
    Laharrague P, Oppert JM, Brousset P, et al. High concentration of leptin stimulates myeloid differentiation from human bone marrow CD34+ progenitors: potential involvement in leukocytosis of obese subjects. Int J Obes Relat Metab Disord 2000; 24: 12126.
  • 53
    Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002; 109: 134550.
  • 54
    Kawanami D, Maemura K, Takeda N, et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004; 314: 4159.
  • 55
    Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004; 89: 44752.
  • 56
    Poullis A, Foster R, Shetty A, Fagerhol MK, Mendall MA. Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2004; 13: 27984.
  • 57
    Soderholm JD, Streutker C, Yang PC, et al. Increased epithelial uptake of protein antigens in the ileum of Crohn's disease mediated by tumour necrosis factor alpha. Gut 2004; 53: 181724.
  • 58
    Suenaert P, Bulteel V, Lemmens L, et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 2002; 97: 20004.
    Direct Link:
  • 59
    Ishiguro Y. Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis. J Gastroenterol 1999; 34: 6674.
  • 60
    Yang R, Han X, Uchiyama T, et al. IL-6 is essential for development of gut barrier dysfunction after hemorrhagic shock and resuscitation in mice. Am J Physiol Gastrointest Liver Physiol 2003; 285: 6219.
  • 61
    Keng X, Wang X, Andersson R. Alterations in endothelial barrier permeability in multiple organs during overactivation of macrophages in rats. Shock 1996; 6: 12633.
  • 62
    Martinez J, Sanchez-Paya J, Palazon JM, Suazo-Barbona J, Robles-Diaz G, Perez-Mateo M. Is obesity a risk factor in acute pancreatitis? A meta-analysis. Pancreatology 2004; 4: 428.
  • 63
    Delgado-Aros S, Locke GR III, Camilleri M, et al. Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. Am J Gastroenterol 2004; 99: 18016.
    Direct Link:
  • 64
    Desreumaux P, Ernst O, Geboes K, et al. Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology 1999; 117: 7381.
  • 65
    Yamomoto K, Kiyohara T, Murayama Y, et al. Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease. Gut 2005; 54: 78996.
  • 66
    Aaronson S. Growth factors and cancer. Science (Washington, DC) 1991; 114653.
  • 67
    Guo YS, Narayan S, Yallampalli C, Singh P. characterization of insulin-like growth factor 1 receptors in human colon cancer. Gastroenterology 1992; 102: 11018.
  • 68
    Warren R, Yuan H, Matli M, Ferrara N, Donner D. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem 1996; 271: 294838.
  • 69
    Krinsley J. S. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc 2004; 79: 9921000.
  • 70
    Dandona P, Mohanty P, Chaudhuri A, Garg R, Aljada A. Insulin infusion in acute illness. J Clin Invest 2005; 115: 206972.
  • 71
    Kaaks R, Toniolo P, Akhmedkhanov A, et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000; 92: 1592600.
  • 72
    Ma J, Giovannucci E, Pollak M, et al. A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst 2004; 96: 54653.
  • 73
    Schoemaker MH, Ros JE, Homan M, et al. Cytokine regulation of pro- and anti-apoptotic genes in rat hepatocytes: NF-kappaB-regulated inhibitor of apoptosis protein 2 (clAP2) prevents apoptosis. J Hepatol 2002; 36: 74250.
  • 74
    Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 1996; 274: 7879.
  • 75
    Van Der Woude CJ, Kleibeuker JH, Jansen PLM, Moshage H. Chronic inflammation, apoptosis and (pre)malignant lesions in the gastro-intestinal tract. Apoptosis 2004; 9: 12330.
  • 76
    Kim PKM, Zamora R, Petrosko P, Billiar TR. The regulatory role of nitric oxide in apoptosis. Int Immunopharmacol 2001; 1: 142141.
  • 77
    Jaiswal M, LaRusso NF, Gores GJ. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am J Physiol 2001; 281: G62634.
  • 78
    Ssaydah SH, Platz EA, Rifai N, et al. Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2003; 12: 4128.
  • 79
    Renehan AG, Shalet SM. Diabetes, insulin therapy, and colorectal cancer. BMJ 2005; 330: 5512.
  • 80
    Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 75967.
  • 81
    Seril DN, Lia J, Yang GY, Yang CS. Oxidative stress and ulcerative colitis associated carcinogenesis: studies in humans and animal models. Carcinogenesis 2003; 24: 35362.
  • 82
    Clevers H. At the crossroads of inflammation and cancer. Cell 2004; 118: 6714.
  • 83
    Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 2002; 94: 97280.
  • 84
    Phillips RW, Wong RK. Barrett's esophagus. Natural history, incidence, etiology, and complications. Gastroenterol Clin N Am 1991; 20: 791816.
  • 85
    Jankowski JA, Wright NA, Meltzer SJ, et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in esophagus. Am J Pathol 1999; 154: 96573.
  • 86
    Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinoma. Cancer Res 1998; 58: 292934.
  • 87
    Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomark Prev 1998; 7: 97102.
  • 88
    Funkhouser EM, Sharp GB. Aspirin and reduced risk of esophageal carcinoma. Cancer (Phila) 1995; 76: 11169.
  • 89
    Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res 1993; 53: 13227.
  • 90
    Vaughan TL, Kristal AR, Blount PL, et al. Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2002; 11: 74552.
  • 91
    Anderson LA, Murphy SJ, Johnston BT, et al. Obesity and smoking in patients with Barrett's esophagus and esophageal adenocarcinoma: results from the Finbar Study. Gastroenterology 2005; 128 (Suppl. 2): A49A50.
  • 92
    Porter KA, Banks PA. Obesity as a predictor of severity in acute pancreatitis. Int J Pancretol 1991; 10: 24752.
  • 93
    Bhatia M. Apoptosis versus necrosis in acute pancreatitis. Am J Physiol 2004; 286: G189G96.
  • 94
    Gukovskaya AS, Perkins P, Zanionovic V, et al. Mechanisms of cell death after pancreatic duct obstruction in the opossum and the rat. Gastroenterology 1996; 110: 87584.
  • 95
    Shoelson SE, Lee J, Yuan M. Inflammation and the IKK beta/I kappa B/NFkappa B axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord 2003; 27 (Suppl. 3): S4952.
  • 96
    Gukovskaya AS, Gukovsky I, Zaninovic V, et al. Pancreatic acinar cells produce, release, and respond to tumor necrosis factor-alpha. Role in regulating cell death and pancreatitis. J Clin Invest 1997; 100: 185362.
  • 97
    Leser HG, Gross V, Scheibenbogen C, et al. Elevation of serum interleukin-6 concentration precedes acute-phase response and reflects severity in acute pancreatitis. Gastroenterology 1991; 101: 7825.
  • 98
    Suzuki S, Miyaska K, Jimi A, Funakoshi A. Induction of acute pancreatitis by cerulein in human IL-6 transgenic mice. Pancreas 2002; 21: 8692.
  • 99
    Zhou W, Levine BA, Olson MS. Platelet activating factor: a mediator of pancreatic inflammation during cerulein stimulation. Am J Pathol 1993; 142: 150412.
  • 100
    Bhatia M, Wong FL, Cao Y, et al. Pathophysiology of acute pancreatitis. Pancreatology 2005; 5: 13244.
  • 101
    Crohn BB, Ginsberg L, Oppenheimer GD. Regional ileitis: a clinical and pathological entity. JAMA 1932; 99: 13239.
  • 102
    Weakley FL, Turnbull RB. Recognition of regional ileitis in the operating room. Dis Colon Rectum 1971; 14: 1723.
  • 103
    Sheehan AL, Warren BF, Gear MWL, Shepherd NA. Fat-wrapping in Crohn's disease: pathological basis and relevance to surgical practice. Br J Surg 1992; 79: 9558.
  • 104
    Mottet NK. Intestinal histopathology of regional enteritis. In: MottetNK, ed. Histopathologic Spectrum of Regional Enteritis and Ulcerative Colitis. Philadelphia, USA: W.B. Saunders, 1971: 63107.
  • 105
    Thompson H. Histopatholgy of Crohn's disease. In: AllanRN, KeighleyMRB, Alexander-WilliamsJ, HawkinsC, eds. Inflammatory Bowel Disease. New York, USA: Churchill Livingstone, 1990: 26385.
  • 106
    Brandtzaeg P. History of oral tolerance and mucosal immunity. Ann N Y Acad Sci 1996; 778: 127.
  • 107
    Cornes JS. Number, size and distribution of Peyer's patches in the human intestine. Gut 1965; 6: 22533.
  • 108
    Herlinger H, Furth EE, Rubesin SE. Fibrofatty proliferation of the mesentery in Croh's disease. Abdom Imaging 1998; 23: 4468.
  • 109
    Knutson H, Lunderquist A. Vascular changes in Crohn's disease. Am J Roentgenol Radium Ther Nucl Med 1968; 103: 3805.
  • 110
    Lin Y, Lee H, Berg AH, et al. The lipopolysaccharide-activated Toll-like receptor (TLR)-4 induces synthesis of the closely related receptor TLR-2 in adipocytes. J Biol Chem 2000; 276: 2425563.
  • 111
    Blain A, Cattan S, Beaugerie L, Carbonnel F, Gendre JP, Cosnes J. Crohn's disease clinical course and severity in obese patients. Clin Nutr 2002; 21: 517.
  • 112
    Bargiggia S, Maconi G, Elli M, et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol 2003; 36: 41720.
  • 113
    Talley NJ, Howell S, Poulton R. Obesity and chronic gastrointestinal tract symptoms in young adults: a birth cohort study. Am J Gastroenterol 2004; 99: 180714.
    Direct Link:
  • 114
    Levy RL, Linde JA, Feld KA, Crowell MD, Jeffery RW. The association of gastrointestinal symptoms with weight, diet, and exercise in weight-loss program participants. Clin Gastroenterol Hepatol 2005; 3: 9926.
  • 115
    Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut 2002; 51: 3056.
  • 116
    Wada K, Nakajima A, Blumberg RS. PPARgamma and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease. Trends Mol Med 2001; 7: 32931.
  • 117
    Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005; 352: 218492.